

United States v. Stevens Case No. 8:10-cr-00694
Defendant's Cross-examination Exhibits

Exhibit No.	Date	Time	Description	Identification	Admitted
D1000	10/05/99		Handout for: The Neuroreceptor Basis of Initial Antidepressant Choice by J. Pradko		
D1001	11/27/03		Copy cover sheet and slides re: What is your favorite antidepressant?		
D1002	10/04/02	5:49 PM	Faxed copy of J. Pradko presentation titled "Neuroreceptor Basis of Initial Antidepressant Choice"		
D1003			Handwritten note from J. Pradko to J. Millar re: lecture, Attaching Powerpoint presentation, "Neuroreceptor Basis of Initial Antidepressant Choice"		
D1004	12/12/02		Letter from L. Stevens to "Doctor" re: Wellbutrin SR (bupropion HCl) Sustained-Release Tablets Request for Presentation Materials Used at GSK-Sponsored Programs (with handwritten notes)		
D1005	01/19/03		Presentation titled "Choosing an Antidepressant of the Long Haul" by J. Pradko		
D1006	08/11/02		Invoice from Bay Pointe Medical Center to M. Chapman/D. Cerajewski for purchase of cassette tapes of "The Neuroreceptor Basis of Initial Antidepressant Choice" (with handwritten notes)		
D1007			Memorandum from M. Pelloquin to J. Pradko outlining "content that legal will be looking for" (with handwritten notes)		
D1008	11/14/02		Invoice from Bay Pointe Medical Center to M. Pelloquin for purchase of cassette tapes of "The Neuroreceptor Basis of Initial Antidepressant Choice"		
D1009	04/27/02		Letter from J. Pradko to M. Pelloquin re: terms of developing audio-visual representation of the Lecture		
D1010	11/30/03		Copy cover sheet and slides re: What is your favorite antidepressant?		
D1011			Glaxo Investigation Document Index		
D1012			Cover letter enclosing 40 cassette tapes and handouts for the lecture entitled "The Neuroreceptor Basis for Antidepressant Choice" paid for by M. Pelloquin		
D1013	07/22/02		Draft letter from J. Pradko confirming booking of J. Pradko to speak		
D1014	10/04/02	4:52 PM	Email from J. Millar to J. Pradko, Attaching "Regulatory Requirements for Speakers"	MAY 5 2011	MAY 5 2011
D1015	11/24/02		Fax cover sheet from J. Pradko to J. Millar with handwritten message, Attaching "Neuroreceptor Basis of Initial Antidepressant Choice"		
D1016			Memos of October 2002 and January 2003 telephone conversations initiated by S. Saini with FDA and GSK participants re: Wellbutrin SR	APR 28 2011	APR 28 2011
D1017	10/16/02	3:16 PM	Memo of 10/16/02 telephone conversation initiated by S. Saini with participants L. Stockbridge, S. Saini, L. Frank, L. Stevens, S. Shade, T. Thelen, D. Snyder, J. Murray re: Wellbutrin SR		
D1018	10/31/02	11:10 AM	Memo of 10/25/02 telephone conversation initiated by S. Saini with participants L. Stockbridge, S. Saini, L. Frank, L. Stevens, S. Shade, T. Thelen, D. Snyder, J. Murray re: Wellbutrin SR		
D1019	01/23/03	11:22 AM	Memo of 1/21/03 telephone conversation initiated by S. Saini with participants L. Stockbridge, S. Saini, L. Frank, L. Stevens, S. Shade re: Wellbutrin SR		
D1020			09/30/02 Letter from A. Davico to R. Katz re: Illegal off-label sales & promotional practices by GlaxoSmithKline Pharmaceuticals; undated letter from S. Saini to A. Davico re: Promotion of Wellbutrin SR		
D1021	10/17/03	10:40 AM	Email from L. Stockbridge to R. Williams, L. Frank, cc'd to S. Saini, T. Abrams re: RE: Wellbutrin SR Inquiry Letter		
D1022	11/13/02	9:18 AM	Email from L. Frank to J. Axelrad, cc'd to T. Schwemer, T. Abrams re: [redacted] 30 day review request		

FILED
LOGGED
ENTERED
RECEIVED

MAY 10 2011

AT GREENBELT
CLERK, U.S. DISTRICT COURT
DISTRICT OF MARYLAND

BY

DEPUTY

United States v. Stevens Case No. 8:10-cr-00694
Defendant's Cross-examination Exhibits

D1023		11/05/02	10:50 AM	Email from S. Saimi to L. Frank, cc'd to L. Stockbridge re: RE: Pre-Disclosure Notification request by GSK		
D1024		10/17/02	8:44 AM	Email from S. Saimi to L. Frank, cc'd to L. Stockbridge re: RE: Wellbutrin SR		
D1025		06/04/98		Letter from L. Frank to M. Hardy re: Glaxo Wellcome Inc. Administrative File MACMIS ID# 6048		
D1026		04/21/98		Fax cover sheet from L. Stevens to L. Frank. Attaching 4/21/98 Letter from L. Stevens to L. Frank re: MACMIS #6048		
D1027		03/16/98		Letter from L. Stevens to L. Frank re: MACMIS #6048		
D1028		12/03/97		Letter from M. Hardy to J. Hankin re: NDA 20-548; FloventO (fluticasone propionate) Inhalation Aerosol, NDA 20-236; SereventO (salmeterol xinafoate) Inhalation Aerosol Speakers' Training Program MACMIS ID #6048		
D1029		11/19/97		Letter from J. Hankin to M. Hardy re: Glaxo Wellcome Inc. Administrative File MACMIS ID# 6048. Attaching fax transmission report and fax cover sheet from J. Hankin to M. Hardy		
D1030		03/10/98		Letter from L. Stevens to L. Frank re: MACMIS #6048		
D1031		02/12/98		Letter from L. Stevens to L. Frank re: MACMIS # 6048		
D1032		06/30/98		Letter from L. Frank to M. Hardy re: Glaxo Wellcome Inc. Administrative File MACMIS ID# 6048		
D1033		01/08/98		Letter from J. Hankin to L. Bendis re: Glaxo Wellcome Inc.'s Speakers' Training Program		
D1034		09/15/03	7:21 AM	Email from C. Balciak to jackie111@comcast.net re: pride programs		
D1035		7/24/2002		DVD Registration Form for K. Conlin for DVD presentation entitled, "The Neuroreceptor Basis of Initial Antidepressant Choice"		
D1036		06/01/02		MEDICAL WORLD CONFERENCES CME EVALUATION FORM RESULTS re: A Primary Care Challenge: Managing Migraine and Depression		
D1037		02/24/01		MEDICAL WORLD CONFERENCES CME EVALUATION FORM RESULTS re: A Primary Care Challenge: Managing Migraine and Depression		
D1038				"Neuroreceptor Basis of Initial Antidepressant Choice" presentation slides by James Pradko, M. Sc., M.D.		
D1039		10/08/02		Fax cover sheet from J. Pradko to J. Millar with handwritten message		
D1040		10/08/02		J. Pradko PowerPoint presentation titled "Neuroreceptor Basis of Initial Antidepressant Choice" (with handwritten notes)		
D1041		01/11/02	6:49 PM	Faxed copy of list of Faculty		
D1042		04/24/02		Letter to J. Pradko (no subject line, with handwriting)		
D1043		10/18/01		Letter to J. Pradko (no subject line, with file folder cover page)		
D1044		12/10/03	1:49 PM	Faxed letter from S. Younger re: Speaker Event Invitation (with handwritten note)		
D1045		07/31/03	5:25 PM	Faxed letter from S. Hamm to J. Pradko requesting Dr. Pradko visit Daytona Beach/Orlando/Jacksonville area in 2004 for WBXL lectures		
D1046		06/14/02		Letter from "A physician practicing in California" to R. Katz. DOCUMENT INFORMATION PAGE and 10/09/02 letter from S. Saimi to M. Martinson re: NDA 20-358 Wellbutrin SR (bupropion HCl sustained-release tablets) MACMIS #11170	APR 27 2011	APR 27 2011

United States v. Stevens Case No. 8:10-cr-00694
 Defendant's Cross-examination Exhibits

D1047	08/07/02	1:31 PM	Email chain from P. Cornell to M. May, L. Rounds, J. Krupa, J. Davignon, L. Wesolowski, G. May, R. Sharma, B. Balk, T. Gerahy, S. Hodges; cc'd to M. Burke, R. Rancourt re: Dr. Sussman's Buffalo Programs on 9-20-02	
D1048	02/19/03	3:17 PM	Email from R. Moscato to S. Helton, L. Fenicchia re: FW: CME	
D1049	01/11/02		Memo from M. Burke to A. Whitaker, J. Millar, D. Slattery, cc'd to C. Singer re: CME	
D1050			Undated feedback on what is working well and what is not working well in the field for Wellbutrin SR	
D1051			Advisory Board PCP/Av. Bd. Agenda Review+Planning 2/14/02 12-1:30pm, 2/25/02 10:00 a.m. Email from S. O'Quinn to J. Millar, J. St. Louis re: Thoughts from PCP KOL Board	
D1052	02/27/02	8:27 AM	Email from J. Millar to S. O'Quinn re: RE: Thoughts from PCP KOL Board (with handwritten notes)	
D1053	05/09/01	9:31 AM	Email from S. Sharo to D. Jones re: FW: Clin Pharm Support for new 200mg and 50mg Wellbutrin SR tablets	
D1054	01/05/02	6:37 PM	Email chain from D. Slattery to M. Burke; cc'd to J. Millar, J. St. Louis, J. Hamaker, D. Childs, T. Bloise, R. Moscato re: RE: James Boudwin Depression #'s	
D1055	09/16/02	4:30 PM	Email from S. O'Quinn to J. Millar, J. St. Louis re: RE: Time Wilens	
D1056	07/29/02	12:29 PM	Email from R. Moscato to J. Hamaker, J. Millar, S. O'Quinn, D. Slattery, J. St. Louis; cc'd to A. Syed re: FW: Indiana Wellbutrin SR LAB July 20, 02 Feedback	
D1057	07/22/02	10:50 AM	Email from D. Slattery to J. Millar, J. Hamaker, S. O'Quinn; cc'd to R. Moscato, J. St. Louis re: FW: July 20th LAB	
D1058	07/29/02	1:15 PM	Email from J. Millar, to A. Syed, R. Moscato, J. Hamaker, S. O'Quinn, D. Slattery, J. St. Louis; cc'd to J. Lawrence, L. Esagro re: RE: Dr. Hudziak and new State law	
D1059	02/04/03	3:55 PM	Email from J. Millar to J. Yohn; cc'd to B. Everly, J. Modell re: RE: Ask Chris/Q	
D1060	04/17/02	5:12 PM	Email from S. O'Quinn to C. Rockett, D. Slattery; cc'd to H. Russell, J. Millar re: RE: Abstracts Accepted to APA	
D1061	04/21/99	10:49 AM	Email from J. Schachle to G. Ormandy; cc'd to J. Murray re: RE: DRAFT Proposed Revisions to Wellbutrin SR (Depression) IP	
D1062	01/30/01	3:19 PM	Email from E. Benson to T. Kline, A. Murray; cc'd to J. Murray re: FW: Historical Question re Wellbutrin SR	
D1063	02/06/01	2:42 PM	Email from S. Learned-Coughlin to J. Murray, J. Almenoff, R. Leadbetter, K. LaCroix re: RE: Wellbutrin Warfarin Letter	
D1064	02/25/03	8:31 AM	Email from J. Murray to M. Martinson; cc'd to E. Benson re: Indication for Adult ADHD	
D1065	07/15/02	3:30 PM	Email from J. Murray to D. Wheadon, E. Benson, M. Martinson re: Wellbutrin SR Remission Data	
D1066	03/18/02	6:48 PM	Email from M. Schwartz to T. Bay, J. Gauzens, J. Golson, G. Hamill, P. Keith, J. Nelson, R. O'Neil, C. Pointer, cc'd to J. Lamb, D. Huber re: FW: APA Info. Attaching list of Abstracts for APA and NCDEU; Schedule of events for APA Convention, Philadelphia, May 18-23	
D1067	04/05/02	12:08 PM	Nichols re: FW: FYI - Wellbutrin SR CME Express ACTION REQUIRED; 4/4/02 Memo from Wellbutrin SR Marketing, R. Moscato to GB Elion Representatives; cc'd to C. Singer, L. Gonzalez, J. Millar re: CME Express Process; CME Express Account Representatives; CME	
D1068	07/05/01	10:50 AM	Email from J. McNeill to A. Long, K. McCrea, H. Mitz, T. Nye, J. Palazzo, J. Parks, M. Register, L. Shepherd re: FW: Press Release from U. of Kentucky	
D1069			Meeting minutes for 1/30/03 meeting with Wellbutrin Team & Strategic Account Team	
D1070	11/25/01	4:28 PM	Email from J. Colley to C. Camino, T. Hart, J. Naugle, M. Rasmussen, A. Rodriguez, S. Sheckler, cc'd to J. Fedell, L. Fenicchia, R. Rancourt, M. Burke re: FW: Keystone Mercy Newsletter	

United States v. Stevens Case No. 8:10-cr-00694
 Defendant's Cross-examination Exhibits

D1071		10/21/03	6:03 PM	Email from D. Stefano to M. Merlo re: RE: Jan7 lecture			
D1072		11/03/02	8:10 PM	Email from H. Polonsky to M. Merlo re: Pradko			
D1073		04/21/03	9:50 PM	Pradko Pride Program 6/13/03, Attaching invocation to "Choosing An Antidepressant For The Long Haul" presentation on 06/13/03 at 6:30 pm			
D1074		02/12/02	11:15 PM	Email from M. Merlo to J. Cavanaugh, E. Divalerio, H. Polonsky, G. Pugliese, L. Raymond, S. Reuss, D. Stefano, T. Thomas re: FW: SUMMARY-NEIL BERLINER PRIDE PROGRAM, Attaching Summary-Dr. Neil Berliner, PRIDE Program-State College, January 16, 2001			
D1075		03/26/02	12:25 AM	Email from M. Merlo to J. Cavanaugh, E. Divalerio, H. Polonsky, G. Pugliese, L. Raymond, S. Reuss, D. Stefano, T. Thomas re: FW: APA Symposia, Attaching schedule of events for APA Convention, Philadelphia, May 18-23			
D1076		05/19/02	5:05 PM	Email from M. Burke to various; cc'd to D. Slattery re: FW: Steve			
D1077		05/10/02	3:39 PM	Email from M. Merlo to J. Cavanaugh, E. Divalerio, H. Polonsky, G. Pugliese, L. Raymond, S. Reuss, D. Stefano, T. Thomas re: FW: Pradko Program			
D1078		05/17/02	5:12 PM	Email from M. Merlo to F. Miller re: FW: Wellbutrin SR information, Attaching completed survey re: Wellbutrin SR			
D1079		1/6/2002	9:38 PM	Trimhath, H. Wenkert, M. Burke, cc'd to M. Beiriger, L. Bell, J. Bove, J. Colley, P. Cornelli, L. Fenicchia, K. Fisher, R. Fonte, S. Heinrichs, D. Hoyland, M. Merlo, F. Miller, S. Morrissey, R. Rancourt, J. Zoltowski re: RE: WEIGHT LOSS REVIEWS; Attaching key points from weight			
D1080		01/22/02	8:54 AM	Email chain from G. Pugliese to M. Merlo re: RE: itinerary for february			
D1081		12/18/00	11:01 PM	Email from M. Burke to M. Beiriger, A. Blanco, J. Bove, J. Colley, L. Fenicchia, A. Holness, T. Mannino, M. Merlo, F. Miller, S. Morrissey, J. Persinger, R. Rancourt, S. Sullivan, J. Zoltowski; Attaching two Program Planning Guides for Philadelphia South District			
D1082		01/25/01	2:26 PM	Email from R. Rancourt to L. Fenicchia, M. B. Beiriger, A. Blanco, J. Bove, J. Colley, A. Holness, T. Mannino, M. Merlo, F. Miller, S. Morrissey, J. Persinger, S. Sullivan, R. Zoltowski; cc'd to M. Burke re: Sample Wellbutrin SR SIB			
D1083		04/13/01	12:51 PM	Zoltowski, cc'd to M. Burke re: Pradko - Hudziak - Green Calendar, Attaching Depression Programming D4 - Independence Region - D4			
D1084		08/13/01	6:21 PM	Pradko - Hudziak - Green Program Schedule - Wellbutrin SR Zoltowski, cc'd to M. Burke re: Pradko - Hudziak - Green Calendar, Attaching Wellbutrin SR: Depression Programming D4 - Independence Region - D4 Pradko - Hudziak - Green Calendar			
D1085		12/23/01	12:58 PM	Merlo, F. Miller, S. Morrissey, D. Nichol, R. Rancourt, J. Zoltowski re: FW: SIB Proposals; Attaching Sales Management Advisory Board Meeting Approval Form, Antihypertetic SIB Agenda, Wellbutrin SR - Special Issue Board questions; Sales Management Advisory Board			
D1086		11/30/01		Notes from SPECIAL ISSUE BOARD NOVEMBER 30, 2001 Dr. James Pradko			
D1087		11/30/01		GlaxoSmithKline Special Issues Board Executive Summary			
D1088		03/11/03	5:01 PM	Email from S. O'Quinn to J. Millar re: L. Gordon re: FW: ADHD FW: Wellbutrin USES by Diag and age.xls; Attaching Market Uses by Age spreadsheet for Wellbutrin			
D1089		10/21/02	4:53 PM	Email from R. Brandon to J. Stephenson, S. Rice, C. Webb, E. Bishop, R. Zoltowski, T. Nichols, R. Rancourt, J. Barnes, A. Syed, T. Andries, A. Killo, D. Merck, G. Dial, G. Romanowksu, M. Schwartz, D. Huber, D. Romeo, cc'd to A. Whitaker re: Migraine CME project			
D1090		09/25/02	6:20 PM	Email from S. Paolella to various re: CNS Sales Monthly Report - Sept. 2002, Attaching September 2002 Monthly Report			
D1091		5/9/2003	7:45 AM	Email from J. Millar to J. Bonomo re: RE: Guidelines	MAY 5 2011	MAY 5 2011	
D1092				Wellbutrin SR presentation slides, R. Rancourt, Sr. Market Development Mgr.			
D1093				Bupropion SR for Weight Loss: Combination with Slim Fast & Exercise presentation slides			
D1094				Glaxo Wellcome Inc. Performance Management report;			

United States v. Stevens Case No. 8:10-cr-00694
Defendant's Cross-examination Exhibits

D1095				Product Flow Chart for Wellbutrin SR			
D1096				Notes from Sarah Atkinson's Talk on 3-2-02			
D1097				Special Issues Boards Executive Summary for Wellbutrin SR, submitted by R. Rancourt			
D1098			03/18/01				
D1099			12/18/00	6:23 PM Email from L. Dowd-Ivanchenko to M. Merlo re: RE: Hudziak/Pradko programs			
D1100			09/28/01	10:35 AM Email from M. Merlo to S. Reuss, J. Cavanaugh, E. Divallero, H. Polonsky, G. Pugliese, L. Raymond, D. Stefano, T. Thomas re: FW: Changes to Prozac Package Insert			
D1101			1/2/2002	10:29 AM Email from M. Merlo to J. Cavanaugh, E. Divallero, H. Polonsky, G. Pugliese, L. Raymond, S. Reuss, D. Stefano, T. Thomas re: FW: James Boudwin Depression #5; Attaching screen shot for J. Boudwin's Anti-Depressant Growth Data			
D1102			01/17/02	11:18 PM Teleconference Slides; Attaching "Sexual Dysfunction and the Treatment of Depression - Wellbutrin SR" presentation slides; Wellbutrin Teleconference 2002 Schedule			
D1103			05/01/00	5:50 PM Moscato to GB Elton Representatives, cc'd to C. Singer, L. Gonzalez, J. Millar, RVPs, MDMs, DSMs, and SROAs re: CME Express Process; CME Express Program Scheduling Form			
D1104			05/09/02	12:52 PM Email from M. Burke to various; cc'd to various re: FW: Grant Request for Dr. London			
D1105			10/01/01	10:59 PM Depression CME Evaluation Results; Attaching Medical World Conferences CME Evaluation Form Results; Managing Depress Sub-types; Atypical Depression in the Primary Care Practice, Philadelphia, PA - September 22, 2001 - Philadelphia Marriott			
D1106			01/17/02	11:14 PM Email from M. Merlo to J. Cavanaugh, T. Thomas re: FW: Wellbutrin SR Slide Kits			
D1107			6/3/2003	12:08 PM Email from A. Harriott to V. Foster re: FW: Obesity brief report			
D1108			02/08/02	4:23 PM Email from J. St. Louis to US Reg Hub MDM/CNS, US Reg Hub RVP/CNS, cc'd to D. Slattery, J. Millar, J. Hamaker, D. Childs, T. Bloise, S. O'Quinn re: Local Advisory Boards -- Wellbutrin SR			
D1109			07/10/02	4:02 PM Email from D. Slattery to J. Millar, S. O'Quinn, J. Hamaker, R. Moscato, J. St. Louis, cc'd to T. Nichols re: FW: D1 Psychiatry Ad Board			
D1110			08/27/01	8/25/01 Special Issues Boards Executive Summary for Wellbutrin SR, submitted by L. Fenicchia			
D1111			05/22/01	5/20/01 Special Issues Boards Executive Summary for Wellbutrin SR, submitted by R. Rancourt			
D1112			05/22/01	5/19/01 Special Issues Boards Executive Summary for Wellbutrin SR, submitted by A. Rancourt			
D1113			11/11/03	8:27 AM Email from M. Martinson to J. Millar re: Re: FW: ADHD Overview; Attaching Wellbutrin summary data for ADHD market			
D1114			03/19/02	5:13 PM Email from J. Modell to J. Millar, cc'd to S. O'Quinn re: RE: Wellbutrin SR Proposal			
D1115			06/19/03	12:15 PM Email from M. Mitton to J. Millar, cc'd to D. Gutterman, G. Cottam, K. Greengrove, L. Gordon, S. O'Quinn, D. Clines re: Re: FW: Information for Japan			
D1116			04/15/03	8:00 PM Email from S. O'Quinn to J. Millar, V. Grosshandler re: RE: Wellbutrin XL PR Plan			
D1117			01/02/03	11:52 AM Email from J. Millar to R. Veeder, V. Carpenter, A. Morgan, S. Holland, S. O'Quinn re: FW: Competitive Threat			
D1118			5/3/2002	10:34 AM Skae, M. Zimic re: FW: New Guidelines; 6/18/02 Memo from M. Burke to D2 District Sales Managers re: New Promotional Guidelines; Speaker event spreadsheet			
D1119			05/06/02	8:34 PM Email chain from K. Fisher to S. Barrett, A. Benvenuti, A. Cascarano, T. Chuckran, M. Clark, S. Hamilton, N. Incanno, N. Kolze, L. Phillips, K. Skae, M. Zimic re: FW: Action Plan, Attaching John Napoli, M.D. Plan of Action			

United States v. Stevens Case No. 8:10-cr-00694
 Defendant's Cross-examination Exhibits

D1119		05/30/02	9:58 AM	Email from K. Fisher to S. Barrett, A. Benvenuti, A. Cascarano, C. Thomas, M. Clark, S. Hamilton, N. Incanno, N. Kolze, L. Phillips, K. Skae, M. Zimic re: FW: New Speakers program update	
D1120		12/18/02	12:42 PM	Email from F. Miller to D. Viggiano, cc'd to R. Rancourt re: Dr. Jeff Green's Presentation	
D1121		12/20/02	12:19 PM	Email from R. Rancourt to K. Farrish re: Coaching Meeting; Attaching 12/20/03 Fax cover sheet from R. Rancourt to K. Farrish re: Coaching Memo	
D1122		12/18/02	10:31 AM	Email from F. Miller to N. Lacagnato, cc'd to R. Rancourt re: Dr. Consagra's Lecture	
D1123		12/19/02	2:30 PM	Swinesburg, A. Pearsall, R. Rancourt re: FW: Description of presentation by Dr. James Pradko; undated communication content sent on behalf of Stan Hull and Lisa Gonzalez	
D1124		01/20/03	5:14 PM	Email from D. Fraser to R. Rancourt, cc'd to J. Zoltowski, L. Gonzalez re: D2 Imitrex & Wellbutrin Fastape Results; Attaching physician survey results for Wellbutrin SR and Imitrex: Region D2 Sales Force, Market Measures/Cozint L.P.	
D1125		02/10/03	12:28 PM	Email from T. Gerahy to R. Rancourt re: FW: Conversation w/Dr. Chawluk	
D1126		02/25/03	9:30 AM	Cascarano re: Must Read: GSK Policy on Non-Independent Speaker Programs; Attachign 2/24/03 Memo from S. Hull to CNS & Respiratory Sales Force Divisions re: GSK Policy on Non-Independent Speaker Programs	
D1127		02/24/03	5:53 PM	Stand Hull, Senior Vice Present of US Pharmaceuticals - RTP Business Unit, To: The CNS and Respiratory Sales Force Divisions; Attaching 2/24/03 Memo from S. Hull to CNS & Respiratory Sales Force Divisions re: GSK Policy on Non-Independent Speaker Programs	
D1128		03/07/03	8:47 AM	Email from R. Rancourt to R. Rancourt re: [no subject]; Attaching draft 2/20/02 memo to [no recipient listed] from R. Rancourt re: Coaching Memo	
D1129		04/07/03	8:16 AM	Email from R. Rancourt to F. Miller re: Re: Hudziak invitation for April 26; Attaching invitation to "Dopamine, Neurotransmitter for the Next Millennium", presented by Dr. James Hudziak	
D1130		05/06/03	11:19 AM	Email from R. Rancourt to J. Zoltowski re: Action Requested; Attaching resume for Randy A. Rancourt, Presentation Template, Business: D2 CNS, Date: 3/20/03	
D1131		05/06/03	11:59 AM	Email from R. Rancourt to L. Gonzalez re: Re: Action Requested; Attaching resume for Randy A. Rancourt	
D1132		08/21/01	7:27 PM	Email from M. Burke to various re: FW: Program on August 4; and 08/06/01 11:43 pm Email from TMI22584@3489 to M. Kohlman, S. Cohen, M. Vester, D. Viggiano, cc'd to M. Merlo, F. Miller re: Hudziak 9/25	
D1133		11/11/00		MEDICAL WORLD CONFERENCES CME EVALUATION FORM RESULTS re: Improving Quality of Life: Successfully Treating Herpes and Managing Depression	
D1134				Plan of Action - Trimester 3, 1998	
D1135		03/13/02	5:14 PM	Email from C. Murphy to M. Abromitis, M. Carey, D. Henning, J. Gouley, D. Haza, R. Lopez re: FW: Reworked Summary Report; Attaching Wellbutrin SR Executive Summary - Wellbutrin SR Local Advisory Board Meeting, January 26, 2002, New York City	
D1136		05/16/01		SPECIAL ISSUES BOARDS EXECUTIVE SUMMARY of 05/12/01 for Wellbutrin SR, submitted by M. Beiriger	
D1137		10/27/02	10:48 PM	Attaching "Managing Depression and Treatment of Obstacles - Wellbutrin SR" presentation slides; "Sexual Dysfunction and the Treatment of Depression - Wellbutrin SR" presentation slides; "Depression and Sexual Dysfunction - Wellbutrin SR" presentation slides; "Sexual	
D1138		04/30/03	8:18 AM	Paquin, M. Sakibura, W. Story, cc'd to R. Rancourt, re: Approved Speaker Topics; Attaching Approved Speaker Program Topics (approved by SE, Marketing and Legal)	
D1139		05/27/03	8:02 AM	Bolton, cc'd to R. Rancourt re: Re: Topic? Hudziak Invitation for Thurs June 5th; Attaching invitation to "Dopamine: Neurotransmitter for the Next Millennium" presented by James Hudziak, M.D.; Approved Speaker Program Topics (approved by SE, Marketing, and Legal)	
D1140		07/10/03	11:11 AM	Quijano, M. Sakimura re: Revised Version! Guest Attendance at Speaker Programs; Attaching memo from S. Hull, L. Gonzalez, K. Lowry to [no recipient listed] re: Guest Attendance at Speaker Programs	
D1141				Wellbutrin SR Basic Training presentation slides	
D1142		05/08/02	3:49 PM	Email from L. Bell to F. Bidwell, K. Carpenter, K. Fenicchia, K. Hutson, C. Hutson, K. Messerschmidt, J. Mitchell-Mclaren, G. Ward, P. Whiting, S. Wright; cc'd to M. Burke re: FW: Pradko Program	

United States v. Stevens Case No. 8:10-cr-00694
Defendant's Cross-examination Exhibits

D1143	09/30/02	2:06 PM	Email from J. Millar to R. Moscato, J. Hamaker, S. O'Quinn, D. Slattery, J. St Louis re: RE: Wellbutrin PRIDE Report		
D1144	12/28/00		PRIDE 2001 Thought Leader Programs for Wellbutrin SR		
D1145	02/28/03	6:19 PM	Email from A. Whitaker to P. Thompson, L. Gonzalez, L. Stevens re: IMMEDIATE ACTION REQUIRED, Attaching REDACTED		
D1146	10/04/02	9:48 AM	Fax cover sheet from J. Pradko to J. Millar re: Slide Rev		
D1147	10/04/02		J. Pradko PowerPoint presentation titled "Neuroreceptor Basis of Initial Antidepressant Choice"		
D1148	11/14/02		Appendix B - GSK Response to Request #5, FDA MACMIS #11170, FDA Letter Date: 10/9/02		
D1149	12/07/01		Template for letter from D. Childs to potential consultants and national speakers for Wellbutrin SR re: National Speaker Agreement terms and conditions		
D1150	12/07/01		Template for letter from D. Childs to potential consultants and regional speakers for Wellbutrin SR re: Regional Speaker Agreement terms and conditions		
D1151			Wellbutrin SR Strategic Objectives		
D1152			PRIDE 2001 biography of J. Pradko		
D1153			Slides of presentation titled "Communication to PCPs" by J. Pradko		
D1154	01/09/03		HCT) Sustained-Release Tablets - Response to GSK Request for Presentation Materials Used at GSK-Sponsored Programs (with handwriting); Attaching PowerPoint presentation (with handwriting)		
D1155	05/17/02		Memorandum from J. Hamaker on behalf of Rob Moscato to L. Gonzalez, cc'd to D. Slattery, J. Millar re: CME Express contract		
D1156	01/29/03	9:30 AM	Calendar Entry re: Medimax CME Review		
D1157			J. Millar PowerPoint presentation titled "2001 in Review"		
D1158	01/24/03	9:00 AM	Calendar Entry re: Updated, Review of the IME and CME Policy		
D1159	06/24/02		Memorandum from R. Moscato to S. Hull; cc'd to D. Slattery, J. Millar re: CME Express PAR module 1		
D1160	07/10/02	10:50 AM	Email from S. Shade to J. Millar, D. Slattery, S. O'Quinn, J. St Louis, J. Hamaker, R. Moscato, M. Martinson, D. Clines; cc'd to J. Ancheta re: Promotional Review Policy		
D1161	12/23/02	3:07 PM	Hull, S. Jose, N. Kuhn, W. Loenard, D. Long, K. Lowry, M. Pucci, C. Sierra, S. Stefano, D. Tulp, D. White, D. Brehm, M. Pittman, D. Pernock, B. Lortie, W. Collier, D. Brand, K. Lokay, J. Murray, K. O'Fee, K. Holowicki, B. Lankford, D. Cocchetto, C. Depew, A. Gustafson,		
D1162	09/19/02	6:00 PM	Calendar Entry from T. Rube to L. Gonzalez, M. Pelloquin, D. Slattery, P. Gaegler, J. Millar, A. Whitake re: CME DVD PRE-MEETING		
D1163	1/2/2002	10:17 AM	Email from S. Paolella to various re: FW: SIBs/LABs		
D1164	1/2/2002	2:10 PM	Email from S. Paolella to various; cc'd to M. Nowell re: FW: Legal Counsel for RTP-based sales forces; Attaching Legal Support for CNS and Respiratory Field Regions		
D1165	10/31/00	8:59 PM	Email from M. Merlo to J. Cavanaugh re: SIB Guidelines and Forms; Attaching Guidelines, Contract, Sample Agenda, Sample Feedback Flowchart, Glaxo Wellcome Special Issues Board Executive Summary, Glaxo Wellcome Program Database Summary Form, Glaxo		
D1166	10/25/00	3:31 PM	Wellcome Advisory Boards Policy and Guidelines, effective January 11, 1999; Advisory Board Consultant Agreement; IBS Regional		

United States v. Stevens Case No. 8:10-cr-00694
Defendant's Cross-examination Exhibits

D1167	09/04/01	5:52 PM	Email from I. Acosta to L. Acosta, A. Davico, E. Guthrie, L. Kearsy, C. Kohler, J. Mirich, D. Smithe, C. Warren, S. Wothe, B. Zieber re: FW: DDMAC Surveillance Activities		
D1168	10/27/02	10:40 PM	Email from R. Rancourt to A. Casarano, RTP US Sales Region D2 - Mgrs. T. Gerahy, M. Burke re: FW: Hudziak Slides - RECALL; Attaching "Novel Approaches to the Selection of Antidepressants" presentation slides by Jim Hudziak, M.D.		
D1169	04/25/03	1:09 PM	Email from M. Hardy to C. Depew re: Re: DDMAC Skills Course RTP Rollout, April 30 9-5; Attaching DDMAC course outline, "Achieving optimal brand communication through effective CAT/DDMAC interaction"		
D1170	10/02/03	10:31 PM	Email from J. Modell to various re: Re: Proposal fro Dr. Kishore Gadde (Duke) to conduct a weight loss study with wellbutrin - more background information		
D1171	04/01/02	8:41 AM	Email chain from M. Burke to various, cc'd to T. Rube, C. Singer re: FW:		
D1172	04/30/02	6:59 PM	Email from D. Fraser to various, cc'd to S. Hull, C. Singer, K. Lowry, K. Bartlett, S. Wolfe re: Advance notice-adoption of new marketing code		
D1173	12/11/01	8:55 PM	Email from U.S. Internal Communications [A. Rajaratnam] to [no names listed in "to" field; long bec list] re: Follow Up - Your High Road Partner; Attaching Pharma Compliance: Your Partner on the High Road	MAY 5 2011	JULY 5 2011
D1174	11/15/02		"NEURORECEPTOR BASIS OF INITIAL ANTIDEPRESSANT CHOICE" by J. Pradko		
D1175	02/28/02	9:31 AM	Email from S. Hull to C. Rubright, cc'd to C. Kelly, A. Rajaratnam, C. Singer re: RE: Denver Investigation (Greg Thorpe)		
D1176	01/02/02	1:10 PM	Email from M. Burke to M. Beiringer, L. Bell, J. Bove, J. Colley, P. Cornell, L. Fenicchia, K. Fisher, R. Fonte, S. Heinrichs, D. Hoyland, M. Merlo, F. Miller, S. Morrissey, D. Nichol, R. Rancourt, J. Zoltowski re: FW: SIBs/LABs		
D1177	04/25/03	12:13 PM	Email from M. Martinson to J. Murray, E. Benson re: DDMAC Skills Course RTP Rollout, April 30 9-5; Attaching DDMAC course outline, "Achieving optimal brand communication through effective CAT/DDMAC interaction"		
D1178	04/01/02		Draft GlaxoSmithKline Standard Operating Procedure for Responding to Unlabeled or Warning Letters from the Division of Drug Marketing, Advertising, and Communications		
D1179	10/09/02	12:21 PM	S. Saini: Attaching undated letter from S. Saini to M. Martinson re: NDA 20-358 Wellbutrin SR (bupropion HCl sustained-release tablets) MACMIS #11170		
D1180	05/19/03	7:54 AM	Email from E. Benson to J. Murray re: Re: Outcome from Commercial Operating Team Meeting: Lamictal Bipolar		
D1181	01/30/02	10:46 AM	Email from J. Millar to J. St. Louis, D. Slattery, D. Childs, J. Hamaker re: RE: Feedback from Field Ad Boards		
D1182	10/09/02	1:06 PM	Email from J. Murray to M. Martinson re: Re: DDMAC letter - summary for review		
D1183	04/11/03	2:34 PM	Email from O. Wolkowitz to M. Brown re: Re: GSK -- Speaker Events		
D1184	04/29/03	2:00 PM	Email chain from L. Stevens to J. Kerr re: FW: Letter to doctors submitting presentation		
D1185	01/06/03	11:41 AM	Email from J. Millar to A. Rosen, M. Pelloquin, A. Whitaker, cc'd to L. Stevens, L. Gonzalez, D. Guterman re: RE: Pradko DVD to Speakers for Wellbutrin SR; Attaching June 2003 draft letter to Dr. "LAST NAME" and 06/24/03 memorandum from S. Hull, D. Tulp to All CNS & Neurohealth RVPs re: Letter to Speakers for Wellbutrin SR		
D1187	02/15/03	8:57 AM	Email from L. Stevens to R. MacRae re: [no subject]		
D1188	06/16/03	1:20 PM	Email chain from L. Stevens to J. Murray re: RE: Wellbutrin SR Key Learnings		
D1189	06/16/03		Memorandum from M. Brown to L. Stevens re: Talking Points for Follow-up Teleconference with FDA Regarding Wellbutrin SR Inquiry		
D1190	10/29/03	5:19 PM	Email chain from S. Shade to R. Moscato re: RE: Questions on PRIDE utilization (without attachments)		

United States v. Stevens Case No. 8:10-cr-00694
 Defendant's Cross-examination Exhibits

D1191		11/18/03	8:28 AM	Email from J. Millar to S. Shade re: RE: Anita Clayton			
D1192		11/06/03	10:17 PM	Email from L. Stevens to P. Seif; cc'd to R. McElhatton, E. Finocchiaro, C. Cummings, T. Thelen, B. Shannon, S. Shade, J. Lemieux, R. Whitlock-Smith re: RE: termination of Aldo Davico			
D1193		12/13/02	2:44 PM	Email from A. Rosen to L. Stevens, S. Shade re: Memo to the File - SOMA Proposal - PRIVILEGED AND CONFIDENTIAL; Attaching 12/13/02 MEMO TO THE FILE from A. Rosen			
D1194		11/07/02	2:22 PM	Email from P. Gaegler to L. Stevens, S. Shade re: FW: D9 2001 Advisory Boards -- Wellbutrin SR, Attaching Glaxo Wellcome Program Database Summary Form			
D1195		11/05/02	10:27 AM	Email chain from L. Stevens to J. Lemieux, T. Thelen, S. Shade, M. Jensen, M. Brown, D. Snyder, J. Hetzel re: Telecon with Lesley Frank			
D1196		11/01/02	5:31 PM	Email from L. Stevens to P. Gaegler, M. Nowell, A. Rosen, cc'd to S. Shade re: [no subject]			
D1197		10/23/02	11:59 AM	Email from S. Shade to J. Lemieux re: FW: CME Express			
D1198		10/09/02	6:29 PM	Email from S. Shade to V. Stowe re: FW: Meeting Notice - Wellbutrin SR DDMAC letter	MAY 5 2011	MAY 5 2011	
D1199		10/21/03	9:27 AM	Email from J. Lemieux to L. Stevens, S. Shade re: Davico - 5 docs mentioned	MAY 3 2011	MAY 3 2011	
D1200		06/25/03	3:45 PM	Email from C. Grant to L. Stevens, cc'd to L. Shoenfelt, C. Rubright, S. Shade, A. Rajaratnam, T. Thelen re: RE: Aldo Davico			
D1201		11/07/02	3:12 PM	Email from A. Rosen to L. Stevens, S. Shade re: FW: WBSR Ad Board Info; Attaching memo from Ann to Randy and Tom; D2 Advisory Boards - Depression - 1/1/2011-10/9/2001			
D1202		12/17/02	12:56 AM	Email chain from L. Stevens to D. Hanley, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, S. Shade, D. Snyder, T. Thelen (no subject line); Attaching GSK Letters to Physicians and Sales Representatives Requesting Promotional Information Draft Questions & Answers			
D1203		02/07/03	12:02 PM	Email from S. Shade to J. Millar re: Dr. Pradko; Attaching DRAFT 2/07/03 letter from L. Stevens to J. Pradko			
D1204		02/04/03	5:56 PM	Email chain from M. Jensen to L. Stevens, S. Shade, cc'd to J. Lemieux, M. Brown, N. Reeves re: FW: Dr. Presentations, K&S Review; Attaching various Review of Doctor Responses dated 1/24/03 documents			
D1205		02/10/03	11:18 AM	Email from S. Shade to M. Martinson, cc'd to J. Murray, E. Benson re: RE: [no subject]			
D1206		02/07/03	12:41 PM	Email from S. Shade to J. Millar re: Dr. Pradko			
D1207		01/18/03	11:43 AM	Email from P. Gaegler to L. Stevens, S. Shade re: RE: Follow-up from sales meeting			
D1208		03/20/03	9:22 AM	Email from J. Lemieux to L. Stevens, S. Shade re: RE: PRIVILEGED/CONFIDENTIAL			
D1209		01/24/03		Various Review of Doctor Responses documents (with handwriting)			
D1210		10/07/02	9:27 AM	Fax cover sheet from J. Pradko to J. Millar; Attaching revised slides of "Neuroreceptor Basis of Initial Antidepressant Choice" (with handwritten notes)			
D1211		02/06/03	10:24 AM	Email from S. Shade to J. Murray, M. Martinson re: [no subject]			
D1212		02/22/03	11:53 AM	Email from L. Stevens to L. Gonzalez, J. Wade, J. Millar re: FDA Investigation re: Wellbutrin Dr. Owen Wolkowitz (without attachment)			
D1213		3/7/2003	2:11 PM	Email from J. Millar to S. Shade re: RE: (no subject)			
D1214		05/29/03	2:39 PM	Email from L. Stevens to J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder (no subject line)			

United States v. Stevens Case No. 8:10-cr-00694
 Defendant's Cross-examination Exhibits

D1215	03/18/03	4:15 PM	pros/cons of submitting physician presentations to FDA. Attaching memo from M. Brown, M. Jensen, N. Reeves to L. Stevens, D. Snyder, S. Shade re: Wellbutrin Investigation. Pros and Cons of Submitting Physician Presentations to FDA dated 3/18/03	
D1216	11/04/02	3:09 PM	Email from J. Lemieux to F. Russell re: PRIVILEGED AND CONFIDENTIAL (with handwritten note)	
D1217	03/17/03	5:28 PM	Email from L. Stevens to J. Lemieux, cc'd to S. Shade re: RE: Speaker Program - wrong topics	
D1218	01/16/03	2:44 PM	Email from L. Esposito to J. Lemieux re: FW: Wellbutrin PRIDE 2001-PRIVILEGED AND CONFIDENTIAL	
D1219	06/26/03		Responses Regarding June 26, 2003 Letter to Doctors Chart	
D1220	04/18/03		NOTE TO FILE from S. Shade	
D1221	02/10/02		Memorandum from D. Childs to D. Stout, S. Hull, L. Gonzalez, J. Millar, cc'd to D. Slattery re: 2002 Wellbutrin SR Teleconference Series	
D1222	10/14/02	10:01 AM	cc'd to E. Benson, J. Modell re: Recent Wellbutrin Publication (Obesity Research). Attaching article by A. Jain, et al., "Bupropion SR vs. Placebo for Weight Loss in Obese Patients with Depressive Symptoms"	
D1223	03/19/03	11:28 AM	Email from L. Stevens to J. Lemieux re: RE:	
D1224	03/07/03	1:43 PM	Email from L. Stevens to J. Lemieux, cc'd to S. Shade re: FW: IMMEDIATE ACTION REQUIRED--PRIVILEGED CONFIDENTIAL	
D1225	03/06/03	7:30 AM	Email from L. Stevens to J. Lemieux re: RVP response	
D1226	03/17/03	5:29 PM	Email from L. Stevens to J. Lemieux re: RE: follow-up on Rep comment	
D1227	06/23/03	1:17 PM	Neurohealth RVPs; cc'd to L. Gonzalez, L. Stevens re: Letter to Speakers for Wellbutrin SR® dated 6/24/03, spreadsheet of addresses, letter from L. Stevens to Dr. LAST NAME re: Wellbutrin SR® (bupropion HCl) Sustained-Release Tablets - Response to GSK Request for	
D1228	12/23/03	4:18 PM	Email from L. Stevens to S. Hull re: Wellbutrin FDA Inquiry	
D1229	11/18/03		MEMO TO CLAYTON FILE re: telephone message from A. Clayton	
D1230	10/29/02	3:11 PM	Email from L. Stevens to D. Snyder, J. Murray, S. Shade, T. Thelen re: October 14, 2002, Attaching 10/29/02 draft letter from L. Stevens to L. Frank re: NDA 20-358 Wellbutrin SR® (bupropion HCl) Sustained-Release Tablets MACMIS #11170	
D1231	10/15/02	3:20 PM	Email from L. Stevens to D. Snyder, J. Murray, S. Shade, T. Thelen re: October 14, 2002, Attaching 10/15/02 draft letter from L. Stevens to L. Frank re: NDA 20-358 Wellbutrin SR® (bupropion HCl) Sustained-Release Tablets MACMIS #11170	
D1232	11/15/02	8:05 PM	Poe, E. Collins, D. Wheadon, cc'd to S. Shade, J. Lemieux, J. Hetzel, M. Werner re: Communications regarding Wellbutrin speaker programs, Attaching 11/18/2002 Memo from L. Stevens to GSK Sales Representative with Promotional Responsibility for Wellbutrin® SR Re: Request	
D1233	10/11/02	4:05 PM	Email from M. Martinson to L. Stevens, S. Shade, J. Lemieux, J. Hetzel, V. Stowe, D. Clines, J. Millar, D. Gutterman, J. Modell, J. Murray, R. DuBose, cc'd to E. Benson re: Wellbutrin SR meetings	
D1234	10/09/02	4:46 PM	to M. Martinson attaching undated letter from S. Saini to M. Martinson re: NDA 20-358 Wellbutrin SR (bupropion HCl) sustained-release tablets MACMIS #11170	
D1235			Greg Thorpe HR File	
D1236	01/15/03	6:30 PM	Merricks, T. Crandall (without attachments), draft GSK (US) Policy on GlaxoSmithKline-Sponsored Speaker Programs dated 02/06/03 (with track changes), draft letter from GlaxoSmithKline dated 10/08/02, draft letter from GlaxoSmithKline dated 02/06/03	
D1237	01/24/03	3:23 PM	Email chain from J. Lemieux to M. Brown, M. Jensen, N. Reeves re: RE: Doctors' Presentations	
D1238	09/19/02		Conference Call objectives re: Use of DVD/CD as a CME vehicle	

United States v. Stevens Case No. 8:10-cr-00694
 Defendant's Cross-examination Exhibits

D1239		10/09/02		Letter from "Jackie" to "Mark" re: Audiovisual products		
D1240		01/06/03	9:06 AM	Email from L. Stevens to A. Rosen, S. Shade re: RE: Reply to email from Jamey Millar - PRIVILEGED AND CONFIDENTIAL		
D1241		12/13/02	3:43 PM	Email from A. Rosen to L. Stevens, S. Shade re: Memo to the File - SOMA Proposal - PRIVILEGED AND CONFIDENTIAL		
D1242		01/06/03	11:59 AM	Email from S. Shade to L. Stevens re: RE: Pradko DVD		
D1243		05/20/02	7:42 AM	Email from A. Rosen to J. Millar, cc'd to S. Shade re: RE: Hudziak	MAY 5 2011	MAY 5 2011
D1244		08/11/03	12:51 PM	Email from C. Stelling to L. Stevens re: RE: Marketing WellbutrinXL give-away		
D1245		09/10/03	1:27 PM	Email from L. Stevens to T. Thelen re: FW: Also Davico		
D1246		09/03/03	12:39 PM	Email from L. Stevens to C. Grant, S. Shade, T. Thelen, A. Rajaratnam, C. Kelly, C. Stelling re: FW: Wellbutrin XL Give Aways		
D1247		08/20/03	5:02 PM	Email from L. Stevens to T. Thelen, C. Grant, S. Shade, A. Rajaratnam re: (no subject)		
D1248		02/07/03		Letter from L. Stevens to J. Pradko re: January 24th meeting		
D1249		05/11/98		Letter from L. Stevens to L. Frank re: MACMIS# 6048		
D1250		02/18/03	7:31 AM	Email from D. Wheadon to L. Wilson, cc'd to C. Jones, P. Gaegler, S. Jose, S. Lyford, M. Werner re: Re: Advair Diskus Speaker Training; Attaching draft agenda for Pulmonary Summit Meeting, Saturday, February 22, 2003		
D1251		12/14/98		Confidential Letter from K. Lowry to M. Burke re: Subject: Final Written Warning		
D1252		10/26/02		Letter from Very Confused to A. Rajaratnam		
D1253				Transcriptions of voicemail messages from M. Burke and Gil (with handwritten notes)		
D1254				Compliance Helpline Issue Details, Case Number: 02032706 re: complaint or report of director and DM managing by intimidation		
D1255		10/07/04	4:37 PM	Email from C. Bode to O. Wolkowitz re: Re: October 28 speaker programs		
D1256		10/22/03	8:51 AM	E-mail from L. Stevens to J. Harp, R. Zolowski, R. Veeder, F. Miller, M. Swann, T. Young, T. Nichols, J. Stephenson, M. Schwartz and D. Huber re: (no subject)		
D1257		04/01/02		Prevalence of Sexual Dysfunction Among Newer Antidepressants by various authors (2002)		
D1258		11/01/05		Bupropion for Major Depressive Disorder: Pharmacokinetic and Formulation Considerations by J. Jefferson, J. Pradko, K. Muir (2005)		
D1259		10/01/02		Antidepressant-induced Sexual Dysfunction by R. Gregorian, K. Golden, A. Balce, C. Goodman, W. Kwong, Z. Khan (2002)		
D1260		12/01/03		Applying neuropharmacology when treating patients with depression by various authors (2003)		
D1261		01/01/10		A New Female Rat Animal Model for Hypoactive Sexual Desire Disorder, Behavioral and Pharmacological Evidence by E. Snoeren, J. Chan, T. Jong, M. Waldinger, B. Olivier, R. Oosting (2010)		
D1262		12/01/07		Symptoms of Sexual Dysfunction in Patients Treated for Major Depressive Disorder: A Meta-Analysis Comparing Selegiline Transdermal System and Placebo Using a Patient-Rated Scale by various authors (2007)		

United States v. Stevens Case No. 8:10-cr-00694
Defendant's Cross-examination Exhibits

D1263	01/01/07	Bupropion HCL and Sleep in Patients with Depression by A. Krystal, M. Thase, V. Tucker, E. Goodale (2007)		
D1264	01/01/08	Catecholamine Reuptake Inhibition Causes Weight Loss by Increasing Locomotor Activity and Thermogenesis by S. Billes, M. Cowley (2008)		
D1265	01/01/08	Effects of bupropion, alone or coadministered with nicotine, on social behavior in mice by C. Gomez, C. Carrasco, R. Redolat (2008)		
D1266	01/01/08	Sexual Counseling in Elderly Coupons by J. Bitzer, G. Platano, S. Tschudin, J. Alder (2008)		
D1267	12/01/03	Putting theory into practice: A challenging case study in the treatment of depression (2003)		
D1268	01/01/10	Antidepressant and Antipsychotic Drugs by A. Krystal (2010)		
D1269	10/01/07	High-Dose Ziprasidone in Treatment-Resistant Schizophrenia and Affective Spectrum Disorders by N. Bergemann, F. Abu-Tair, K. Kress, P. Parzer, J. Kopitz (2007)		
D1270	12/11/09	Declaration of Robert Temple, M.D. filed in Case 1:09-cv-01879-JDB		
D1271	03/29/10	Supplemental Declaration of Robert Temple, M.D. filed in Case 1:09-cv-01879-JDB		
D1272	01/07/10	Defendants' Memorandum of Points and Authorities in Support of Motion to Dismiss or for Summary Judgment in <i>Allergun, Inc. v. United States</i> (Case 1:09-cv-01879-JDB)		
D1273	03/29/10	Defendants' Reply in Support of Motion to Dismiss or for Summary Judgment and Response to Cross-motion for Summary Judgment in <i>Allergun, Inc. v. United States</i> (Case 1:09-cv-01879-JDB)		
D1274	10/03/02	Draft OIG Guidance for Pharmaceutical Manufacturers, 67 Fed. Reg. 62057		
D1275	10/08/10	Brief and Special Appendix for the United States in <i>United States v. Coriano and Gleason</i> , Docket No. 09-5006-cr(L), US Court of Appeals for Second Circuit		
D1276	09/10/02	Lesley Frank PowerPoint Slides: Overview of Direct-to-Consumer Promotion of Rx Drugs		
D1277	09/23/03	Lesley Frank PowerPoint Slides: Promotion and Marketing of Prescription Drugs		
D1278	09/10/02	Transcript of Federal Trade Commission's "Health Care and Competition Law and Policy Workshop"		
D1279	08/05/09	Ex Parte, In Camera Declaration of Mark S. Brown In re Grand Jury Subpoena to GlaxoSmithKline		
D1280	11/27/92	Draft Policy Statement on Industry-Supported Scientific and Educational Activities, 57 Fed. Reg. 56,412		
D1281	11/18/94	Citizen Petition Regarding FDA's Policy on Promotion of Unapproved Uses of Approved Drugs and Devices; Request for Comments, 59 Fed. Reg. 59,820		
D1282	12/08/95	Advertising and Promotion; Draft Guidelines; Republication, 60 Fed. Reg. 63,384		
D1283	10/08/96	FDA Guidance on Advertising and Promotion, 61 Fed. Reg. 52,800		
D1284		Federal Food Drug and Cosmetic Act FDC Act/Significant Amendments to the FDA Act		
D1285	06/08/98	Dissemination of Information on Unapproved/New Uses for Marketed Drugs, Biologics, and Devices, 63 Fed. Reg. 31,143		
D1286	07/30/98	<i>WLF v. Friedman</i> , 13 F. Supp. 2d 51 (D.D.C. 1998)		

United States v. Stevens Case No. 8:10-cr-00694
 Defendant's Cross-examination Exhibits

D1287	12/03/97		Final Guidance on Industry-Supported Scientific and Educational Activities 62 Fed. Reg. 64,074	
D1288	02/16/99		<u>WLF v. Friedman</u> , 36 F. Supp. 2d 16 (D.D.C. 1999)	
D1289	04/15/99		Putting a Mistake Behind It, Genentech Pays a \$50 Million Fine, <u>Business Week</u>	
D1290	07/28/99		<u>WLF v. Henney</u> , 56 F. Supp. 2d 81 (D.D.C. 1999)	
D1291	01/11/00		<u>WLF v. Henney</u> , 202 F.3d 331 (D.C. Cir. 2000)	
D1292	03/16/00		FDA Notice Decision in <u>Washington Legal Foundation v. Henney</u> , 65 Fed. Reg. 14286	
D1293	11/30/00		<u>WLF v. Henney</u> , 128 F. Supp. 2d 11 (D.D.C. 2000)	
D1294	11/07/01		Oxycontin Marketing Probed, by Michele Handler, <u>Miami Herald</u>	
D1295	01/01/04		Code on Interactions with Healthcare Professionals	
D1296	05/16/02		Request for Comment on First Amendment Issues, Department of Health and Human Services, FDA Docket No. 02N-0209	
D1297	08/17/02		Lilly Subpoenaed over Marketing of Evista, <u>Washington Drug Letter</u>	
D1298	11/25/02		S-P Served with Fresh Set of Subpoenas, <u>Pharma Marketletter</u>	
D1299	04/03/11		Office of Inspector General: Compliance Program Guidance for Pharmaceutical Manufacturers	
D1300	06/20/03		Department of Justice: Press Release: Astrazeneca Pharmaceuticals LP Pleads Guilty to Healthcare Crime	
D1301	01/01/04		Preamble to the 2004 Updated ACCME Standards for Commercial Support	
D1302	02/09/07		Testimony Before the House Oversight and Government Committee: Lewis Morris	
D1303	02/20/08		Publications on Unapproved New Uses of Approved Drugs and Approved or Cleared Medical Devices: Availability, Department of Health and Human Services, FDA Docket No. FDA-2008-D-0052	
D1304	01/13/09		Publications on Unapproved New Uses of Approved Drugs and Approved or Cleared Medical Devices: Availability, Department of Health and Human Services, FDA Docket No. FDA-2008-D-0053	
D1305	01/04/11		21 U.S.C. 331 (prohibition on misbranding)	
D1306			21 U.S.C. 352 (defining "misbranding," including "adequate directions for use" requirement)	
D1307	06/22/09		21 U.S.C. 321 (definition of labeling)	
D1308			21 CFR 201.128 (defining "intended use")	
D1309			21 CFR 201.5 (defining adequate directions for us)	
D1310	01/25/10		21 CFR 314.81 (DDMAC's 2253 process)	

United States v. Stevens Case No. 8:10-cr-00694
Defendant's Cross-examination Exhibits

D1311	02/19/08		21 C.F.R. 202.1 (permitting comparative claims where supported by "substantial evidence", further defining "labeling")		
D1312			21 C.F.R. 314.126 (defining clinical evidence required to constitute "substantial evidence" under 21 CFR 202.1)		
D1313	12/01/10		Micromedex Drugdex Evaluations - Database Updated December 2010 - Bupropion		
D1314	12/01/10		Micromedex DrugPoints System - Database Updated 20101201 - Bupropion Hydrochloride		
D1315	01/01/11		AHFS Drug Information		
D1316	06/09/03		6/9/03 Letter from Davico to DDMAC		
D1317	01/17/01		01/17/01 2253 Material		
D1318	01/19/11		01/19/01 2253 Material	APR 28 2011	APR 28 2011
D1319	04/26/01		04/26/01 2253 Material		
D1320	05/04/00		05/04/00 2253 Material		
D1321	02/15/00		02/15/00 2253 Material	APR 28 2011	APR 28 2011
D1322	12/09/99		12/09/99 2253 Material		
D1323	10/27/00		10/27/00 2253 Material	APR 28 2011	APR 28 2011
D1324	08/17/99		08/17/99 2253 Material	APR 28 2011	APR 28 2011
D1325	04/20/00		04/20/00 2253 Material		
D1326	03/20/97		03/20/97 2253 Material	APR 28 2011	APR 28 2011
D1327	08/13/97		08/13/97 2253 Material		
D1328	10/08/02		10/08/02 2253 Material	APR 28 2011	APR 28 2011
D1329	09/17/02		09/17/02 2253 Material		
D1331	09/24/03	11:24 AM	09/24/03 Email from Lauren Stevens to Julie Lemieux and Sherri Shade re: FW Removal of Dr. Kishore Gadde from SE		
D1332	06/12/03	12:57 PM	06/12/03 Email from Sherri Shade to Karen Kilburn re: Speaker list and letter (with attachment)	APR 28 2011	APR 28 2011
D1333	10/01/03	2:32 PM	10/01/03 Email from Lauren Stevens to Debbie Foreman, Laurie Hedgpath re: Removal of Dr. Dori Middleman	MAY 3 2011	MAY 3 2011
D1334	09/19/03	3:12 PM	09/19/03 Email from Lauren Stevens to Allan Morgan re: Response Required by September 26, 2003		
D1335	09/23/03	1:53 PM	09/23/03 Email from Debbie Foreman to Lauren Stevens, Laurie Hedgpath re: RE: Removal of Dr. Steven Levine from GSK Speaker Event database		

United States v. Stevens Case No. 8:10-cr-00694
 Defendant's Cross-examination Exhibits

D1336	06/26/03	6/26/03 Letters to doctors re: Wellbutrin presentations - signed	MAY 3 2011	MAY 3 2011
D1337	04/01/94	Current Issues and Procedures; Division of Drug Marketing, Advertising and Communications		
D1338	02/01/01	February 1, 2001 Warning Letter from Thomas Abrams to Fred Hassan		
D1339	12/03/97	12/3/1997 Article regarding Guidance for Industry Industry-Supported Scientific and Educational Activities		
D1340	09/17/01	September 17, 2001 Warning Letter from Thomas Abrams to Raymond Gilmartin		
D1341	04/30/09	Regulatory Information SEC 906 [21 USC 396]		
D1342	01/01/09	Wellbutrin Prescribing Information		
D1343	04/17/03	April 17, 2003 letter to Lana Ogram from Andy Mao re US ex rel. Gregory Thorpe and Blair Hamrick v. GSK, Inc.		
D1344	06/11/03	6/11/03 Email from Rebecca Williams to Lesley Frank and Rebecca Williams re DOJ Investigation		
D1345	06/30/03	Letter to Andy Mao from Sonny Saini re GSK Off-Label Promotion of Wellbutrin SR	APR 27 2011	APR 27 2011
D1346	11/14/03	11/14/03 Email from R. Williams to Terry Martin cc-ing T. Abrams, L. Stockbridge, S. Saini, L. Frank, and R. Williams re DOJ request-Wellbutrin SR		
D1347	11/17/03	Email dated 11/17/03 from L. Stockbridge to R. Williams, L. Frank cc-ing S. Saini and T. Abrams		
D1348	10/16/03	Email dated 10/16/03 from R. Williams to L. Frank cc-ing L. Stockbridge, S. Saini, and T. Abrams re Wellbutrin SR Inquiry Letter		
D1349	01/26/11	Letter dated 1/26/11 to W. Hassler from P. Jasperse regarding US v. Lauren Stevens, RWT-10-0694 (D. Md.)		
D1350	10/17/03	Email dated 10/17/03 from M. Brown to L. Stevens, S. Shade, N. Reeves, J. Lemieux, D. Snyder, and T. Thelen regarding DDMAC Contact		
D1351	09/30/03	Letter dated 9/30/03 from S. Saini to A. Davico re Promotion of Wellbutrin SR		
D1352	04/01/10	CFR Title 21		
D1353	11/12/02	Email dated 11/12/02 from Tawni Schwemer to L. Frank and Donna Katz re pre-disclosure notification request by GSK		
D1354	04/19/11	Application for Trial Testimony Immunity (Docket Number 157)		
D1355	03/12/02	Speaker Notes Presentation		
D1356	01/01/02	2002 SI POA Presentation		
D1357	01/02/03	Email dated 01/02/03 from J. Millar to S. O'Quinn, Robert Moscato, Jeanene (Stegemeier) Hamaker, Julia St. Louis, David Smithwick, Deirdre Slattery, Golda Ellis, Erin Clarke, Amy Zgonce		
D1358	01/14/03	Email dated 01/14/03 from Amy Zgonce to Graham Cottam and Cath Harvey and others cc-ing Millar re FW. 2003 WBSR/XL Brand Team Responsibilities		
D1359	01/08/04	Email dated 1/8/04 from Millar to J. Hamaker, D. Smithwick, and others re Sign off		

United States v. Stevens Case No. 8:10-cr-00694
 Defendant's Cross-examination Exhibits

D1360		02/17/11		Letter dated 2/17/11 to W. Hassler from S. Bloom regarding Discovery in US v. Stevens		
D1361		06/04/01		Email dated 6/4/01 from Stout, Hull, Daly, Skolsky, Pernock, Jahara, Lokay, Stefano, White to GSK US Pharma Personnel regarding New GSK Policies on Commercial Practices		
D1362		01/02/02		Email dated 01/02/02 from Arjun Rajaratnam to GSK Sales Force re Pharma Compliance		
D1363		05/13/02		Email dated 05/13/02 from Joy West to Jim Labb and Fred Gregg cc-ing Ned Schneidewind, Jerry Nelson, Arnie Casciato, W (US Sales), Barbara Curtin, Pat Keith regarding Pharma Compliance		
D1364		10/24/02		Email dated 10/24/02 from Group Mailbox US Pharma Internal Communications to K. Lowry, L. Gonzalez, W. Collier, and others re Important New Revisions to GSK Commercial Practices Policies		
D1365		05/18/02		Email dated 05/18/02 from James Millar to Ann Rosen and Sherrie Shade re Hudziak		
D1366		10/09/02		Slide 46: Most Common Side Effects--Package Insert	MAY 5 2011	MAY 5 2011
D1367		01/27/04		Hudziak Resume		
D1368		02/08/03		Email dated 2/8/03 from Sean Bowler to Frank Liu regarding Wellbutrin SR National Speakers	MAY 5 2011	MAY 5 2011
D1369		02/22/02		Agreement with GSK National Speaker Promotional Programs (P.R.I.D.E.)		
D1370		09/16/02		Email dated 9/18/03 from Guyer to Bean and others regarding WXL Teleconference schedule	MAY 5 2011	MAY 5 2011
D1371		09/21/03		Email dated 09/21/03 from Winston Churchill to Scott Berger, Patty Newman and others re (Action) Dr. Hudziak Teleconferences		
D1372		11/07/03		Email dated 11/07/03 from Bill Judd to Gwen Armstrong, David Brand and others re Confidential: Professional Programs Compliance Review - Third Quarter 2003		
D1373		09/30/03		Compliance Review Highlights--Third Quarter 2003 (Professional Programs)		
D1374		09/30/03		Compliance Review Highlights--Third Quarter 2003 (Professional Education)		
D1375		01/05/04		Top 10 Speakers		
D1376		04/15/09		Email dated 4/15/09 from L. Stockbridge to S. Tave re April 16		
D1377		05/23/02		Email dated 05/23/02 from jogle@zoo.uvm.edu to Jill Sharp re New Slides for Dr.		
D1378		00/00/00		Novel Approaches to the Selection of Antidepressants Powerpoint		
D1379		12/08/01		Managing Depressive Sub-types: Atypical Depression in the Primary Care Practice		
D1380		11/09/02		Managing Depressive Sub-types: Atypical Depression in the Primary Care Practice		
D1381		12/12/02		Email dated 12/12/02 from Bean to Galton and Nichols regarding Syracuse CME activity results		
D1382		08/15/02		Email dated 08/15/02 from Nichols to Moscato and Delea regarding CME Express program 9/5-Hudziak		
D1383		10/29/02		Email dated 10/29/03 from Hugh McAleer to Lauren Stevens and others regarding Teleconference Slides		

United States v. Stevens Case No. 8:10-cr-00694
 Defendant's Cross-examination Exhibits

D1384	11/03/03		Email dated 11/03/03 from Colleen Connelly to Natalie Coy and others regarding November 10 Hudziak teleconference	MAY 5 2011	MAY 5 2011
D1385	12/16/03		Email dated 12/16/03 from Stevens to Lemieux regarding	APR 28 2011	APR 28 2011
D1386	04/20/00		04/20/00 2253 Material (Pradko)		
D1387	12/22/99		12/22/99 2253 Material		
D1388	08/05/02		GSK Representative Program Evaluation Form		
D1389	07/29/02		GSK Representative Program Evaluation Form		
D1390	07/29/02		GSK Representative Program Evaluation Form		
D1391	00/00/00		James Pradko's Resume	MAY 5 2011	MAY 5 2011
D1392	11/18/99		Information for Introduction of James Pradko, MSc, MD		
D1393	00/00/00		Bio of James Pradko		
D1394	00/00/00		GSK Agreement with Speaker Events Member Promotional Programs		
D1395	00/00/00		Treatment regimens for managing depression in family practice		
D1396	00/00/00		From paper to patient. How do you translate science into clinical practice		
D1397	00/00/00		Response to treatment. Gaining and maintaining remission from depression		
D1398	00/00/00		The scope of the problem. Physical symptoms of depression		
D1399	00/00/00		Depression and comorbid medical illness. Therapeutic and diagnostic challenges		
D1400	11/15/04		15 Years of Clinical Experience with Bupropion HCL. From Bupropion to Bupropion SR to Bupropion XL		
D1401	00/00/00		A 4-step program for the diagnosis and management of depression		
D1402	00/00/00		The Neuroreceptor Basis of Initial Antidepressant Choice		
D1403	00/00/00		The Neuroreceptor Basis of Initial Antidepressant Choice		
D1404	03/06/02		Email dated 3/6/02 from JS20795@3489 to K. Connor, J. Corrigan, D. Julia and others re FW: How well do you know your customers?		
D1405	02/01/00		The Doctor as Customer A Guide for Pharmaceutical Representatives		
D1406	10/24/02		Email dated 10/24/03 from G. Bean to Peter Difazio re Dr. Jim Pradko Tour Nov 19-21	MAY 5 2011	MAY 5 2011
D1407	11/07/03		Email dated 11/07/03 from Tracey Dance to Pradko re Dec 5 Memphis TN		

Exhibit No.	Date	Time	Description	BegBates	EndBates	Identification	Admitted
D1412	12/10/03		Letter from James Millar to James Pradko regarding the conversation of December 4, 2002	GSKCO-0228-000045	GSKCO-0228-000046		
D1413	00/00/09		Hypnosis in Treating Symptoms and Risk Factors of Major Depression (2009)	Y003291	Y003299		
D1414	00/00/97		Bupropion Treatment of Serotonin Reuptake Antidepressant-Associated Sexual Dysfunction	Y003301	Y003305		
D1415	06/02/10		Tolerance to desvenlafaxine in rapid metabolizing depressed patients (2011)	Y003306	Y003309		
D1416	00/00/97		Combining Serotonin Reuptake Inhibitors and Bupropion in Partial Responders to Antidepressant Monotherapy	Y003310	Y003318		
D1417	09/26/03		Email dated 09/26/03 from Alan Metz to Jack Modell re Wellbutrin Query Gadde	GSKCO-0083-044532	GSKCO-0083-044536		
D1418	10/09/02		Email dated 10/09/02 from Jeanene Hamaker to Julia St. Louis re Correspondence from DDMAC-Wellbutrin SR	GSKCO-0226-003698	GSKCO-0226-003699	MAY 5 2011	MAY 5 2011
D1419	05/15/03		Email dated May 15, 2003 from Lauren Stevens to Stan Hull, Donna Guterman, James Millar re Draft Final Submission to FDA re: WBSR	GSKCO-0252-033488	GSKCO-0252-033488	MAY 5 2011	MAY 5 2011
D1420	02/25/02		Email dated 2/25/02 from Stephen O'Quinn to James Millar, Julia St. Louis re Thoughts from PCP KOL Board	GSKCO-0002-017457	GSKCO-0002-017461		
D1421	05/01/03		Email dated 5/1/03 from Stevens to Burkes re Letters to doctors submitting presentations	GSKCO-0252-014680	GSKCO-0252-014684		
D1422	00/00/00		Biography of Owen Wolkowitz, Department of Psychiatry	Y003320	Y003321		
D1423	02/22/03		Email dated 2/22/03 from Stevens to Owen Wolkowitz re Wellbutrin Sales	GSKCO-0208-000017	GSKCO-0208-000021		
D1424	00/00/98		Bupropion Treatment of Serotonin Reuptake Antidepressant-Associated Sexual Dysfunction	Y003301	Y003305		
D1425	06/03/10		Tolerance to desvenlafaxine in rapid metabolizing depressed patients (2011)	Y003306	Y003309		
D1426	00/00/98		Combining Serotonin Reuptake Inhibitors and Bupropion in Partial Responders to Antidepressant Monotherapy	Y003310	Y003318		
D1427	09/26/03		Email dated 09/26/03 from Alan Metz to Jack Modell re Wellbutrin Query Gadde	GSKCO-0083-044532	GSKCO-0083-044536		
D1428	10/09/02		Email dated 10/09/02 from Jeanene Hamaker to Julia St. Louis re Correspondence from DDMAC-Wellbutrin SR	GSKCO-0226-003698	GSKCO-0226-003699		
D1429	05/15/03		Email dated May 15, 2003 from Lauren Stevens to Stan Hull, Donna Guterman, James Millar re Draft Final Submission to FDA re: WBSR	GSKCO-0252-033488	GSKCO-0252-033488		

United States v. Stevens Case No. 8:10-cr-00694
Defendant's Cross-examination Exhibits

D1408	10/03/03		Letter dated 10/03/03 to James Pradko from Stephen O'Quinn, Director of Wellbutrin Marketing		
D1409	11/02/03		Wellbutrin XL National Advisory Board Final Attendees		
D1410	10/12/03		Email dated 12/12/03 from Jpradko to Shelly Prather re Nashville TN Speaking Dates		
D1411	12/10/03		Letter from James Millar to James Pradko regarding the conversation of December 4, 2002		
D1430	01/02/03		Letter dated January 2, 2003 from John Ates to Belinda Shannon, Assistant General Counsel for GSK regarding Matthew Burke		
D1431	06/29/01		Email dated 6/29/01 from Rick Mazzetti to US SF Sector CNSVP Managers and others		
D1432	08/25/03		Email dated 08/25/03 from L. Stevens to Cary Grant, Tim Thelen and others re ONA conference 2 Grant requests		
D1495	11/07/02		Email chain regarding D9 2991 Advisory Boards-Wellbutrin SR (with attachments)		
D1496	00/00/00		Speaking Event Sheet/Expense form for Jack Modell		
D1497	00/00/00		Speaking Event Sheet/Expense form for David Dunner		
D1498	00/00/00		Speaking Event Sheet/Expense form for Fred Goodwin		
D1499	00/00/00		Documents from the "Hanley-Lemieux Correspondence tag" (23 documents in total, sorted by date)	APR 29 2011	APR 29 2011
D1500	04/25/03		Email dated 4/25/03 from L. Frank to T. Abrams and R. Williams re DOJ request/Wellbutrin SR/DDMAC inquiry	APR 28 2011	APR 28 2011
D1501	04/25/03		Email dated 4/25/03 from L. Frank to L. Stockbridge, B. Marques, S. Saini, R. Williams, S. Salis, and T. Abrams		
D1502	05/12/03		Email dated 5/12/03 from L. Frank to L. Stockbridge re Department of Justice Investigation	APR 28 2011	APR 28 2011
D1503	06/11/03		Email dated 6/11/03 from R. Williams to T. Abrams, L. Frank, and R. Williams re DOJ Investigation		
D1504	11/14/03		Email dated 11/14/03 from Rebecca Williams to Terry Martin, Thomas Abrams, Lisa Stockbridge and others re DPJ request--Wellbutrin SR	APR 28 2011	APR 28 2011
D1505	10/17/03		Email dated 10/17/03 from Rebecca Williams to L. Stockbridge, L. Frank, S. Saini, and T. Abrams re Wellbutrin SR Inquiry Letter	APR 28 2011	APR 28 2011
D1506	11/13/02		Email dated 11/13/03 from T. Schwemer to L. Frank re OCC 30 day review request		
D1507	07/27/06		Email dated 7/27/06 from Hermisen to Towns re Potential Off-Label claims for Wellbutrin		
D1508	11/09/06		Email dated 11/9/06 from K. Towns to L. Frank and K. Davis re GSK		
D1509	11/15/06		Email dated 11/15/06 from Davis to L. Frank re Wellbutrin	APR 28 2011	APR 28 2011
D1510	11/09/06		Email dated 11/9/06 from Saini to Karen Towns, Elaine Cunningham, Joan, Hanklin, L. Stockbridge re GSK		
D1511	02/06/04		Letter dated 2/6/04 from John Suthers to Thomas Lee, II re USAO Subpoena No. 04-0036 Investigation of GlaxoSmithKline		

51

Exhibit No.	Date	Time	Description	BegBates	EndBates	Identification	Admitted
D1517	04/02/03		Email from Damien Clark to Sherrie Shade, Lauren Stevens, Julie Lemieux re: Breakdown of Kit 75 Recipients				
D1518	10/22/03		Aldo Davico's Human Resource file	GSKCO-0252-067135	GSKCO-0252-067170		
D1519	02/01/11		Email chain with the bottom email from Robyn Feeley to Cathleen Hanwell, Joann Dudek and Carolyn Thomas re: Hudziak Slides (with attachment)	GSKCO-0019-050839	GSKCO-0019-050846		
D1520	11/15/01		Email chain with the bottom email to Carol Camino, Tammy Hart, Jeffrey Naugle, Michael Rasmussen, Andres Rodriguez, Stephanie Sheckler re: Hudziak Slides (with attachment)	GSKCO-0026-078165	GSKCO-0026-078178		
D1521	12/02/02		Email from Lauren Stevens to Owen Wolkowitz	GSKCO-0208-000008	GSKCO-0208-000010		
D1522	00/00/06		Use of Bupropion in Combination with Serotonin Reuptake Inhibitors (2006)				
D1523	00/00/01		Bupropion SR in the naturalistic treatment of elderly patients with major depression (2001)				
D1524	11/07/01		A Placebo-Controlled Comparison of the Effects on Sexual Functioning of Bupropion Sustained Release and Fluoxetine (2001)				
D1525	03/00/01		Substitution of an SSRI With Bupropion Sustained Release Following SSRI-Induced Sexual Dysfunction (2001)				
D1526	05/27/04		A review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor (2004)				
D1527	02/11/03		Letter from Julie Lemieux to Jeffrey Zerby	GSKCO-0155-006373	GSKCO-0155-006373	MAY 3 2011	MAY 3 2011
D1528	12/27/02		Letter from Debra Bolick to Lauren Stevens	GSKCO-0155-006879	GSKCO-0155-006879		
D1529	01/11/03		Letter to GSK from Dori Middleman	GSKCO-0155-008380	GSKCO-0155-008382		
D1530	01/13/03		HW note to Lauren Stevens from Clyde	GSKCO-0155-006325	GSKCO-0155-006325		
D1531	12/26/02		Letter from Lauro Amezcua to GSK	GSKCO-0155-006499	GSKCO-0155-006499	MAY 3 2011	MAY 3 2011
D1532	01/07/03		Email from Boghos Yerevanian to Julie Lemieux re: GSK letter dated 12/12/2002	GSKCO-0155-006346	GSKCO-0155-006346	MAY 3 2011	MAY 3 2011
D1533	10/28/03		Memorandum from Mark Brown to Lauren Stevens re: Dan Smith Interview Summary	GSKCO-0252-069957	GSKCO-0252-069960		
D1534	11/07/02		Email from S. Shade to Julie Lemieux re: WellbutrinSR Advisory Board Information for Region B8	GSKCO-0252-020471	GSKCO-0252-020490	MAY 3 2011	MAY 3 2011

Exhibit No.	Date	Time	Description	BegBates	EndBates	Identification	Admitted
D1535	11/07/02		Email from S. Shade to Julie Lemieux re: D9 2001 Advisory Boards-Wellbutrin	GSKCO-0252-025021	GSKCO-0252-025028		
D1536	00/00/00		Reward for Excellence (Compensation Packet)	GSKCO-0252-112922	GSKCO-0252-112932		
D1537	00/00/01		Lauren Stevens 2001 Evaluation	GSKCO-0202-000257	GSKCO-0252-000272		
D1538	10/28/03		Email dated 10/28/03 from April Harriett to Stephen O'Quinn re Wellbutrin Sect	GSKCO-0083-041127	GSKCO-0083-041135		
D1539	04/17/02		Email from Stephen O'Quinn to Carol Rickett and Deidre Slattery re: Abstracts Accepted to APA	GSKCO-0007-055779	GSKCO-0007-055781		
D1540	06/19/03		Email from Melinda Milton to James Millar re: Information for Japan	GSKCO-0068-094908	GSKCO-0068-094910		
D1541	11/11/03		Email from Mary Martinson to James Millar re: ADHD Overview	GSKCO-0055-013161	GSKCO-0055-013175		
D1542	01/11/99		Glaxo Wellcome Advisory Boards Policy and Guidelines	GSKCO-0157-001912	GSKCO-0157-1916		

Exhibit No.	Date	Time	Description	BegBates	EndBates	Identification	Admitted
D1543	07/25/03		Email chain with a top email from Lauren Stevens to Aldo Davico re: July 31 Meeting	GSKCO-0218-000300	GSKCO-0218-000301		
D1544	03/04/03		Teleconference on Feb 26, 2003 with Dr. Owen Woljowitz, L. Stevens, M. Brown, M. Jensen, and Nikki Reeves	GSKCO-0252-054530	GSKCO-0252-054532		

Exhibit No.	Date	Time	Description	BegBates	EndBates	Identification	Admitted
D1545	10/20/03		Email dated 10/20/03 from Lauren Stevens to Sherrie Shade re Memo	GSKCO-0252-014461	GSKCO-0252-014462		
D1546	07/03/03		Email dated 7/03/03 from Lauren Stevens to Mark Jensen, Mark Brown, and others re Draft Responses to Potential FDA Conf. Call	GSKCO-0252-076556	GSKCO-0252-076568		
D1547	06/16/03		Email dated 6/16/03 from Lauren Stevens to Mark Jensen, Mark Brown, Nikki Reeves, et al re Draft Responses to Potential FDA Conf. Call Questions	GSKCO-0252-057269	GSKCO-0252-057270		
D1548	09/09/04		House of Representatives Energy and Commerce Anti-Depressant Use Among Children				